Shizuoka Cancer Center (SCC)

Shizuoka 411-8777

1 studies enrolling now · 2 studies all time

What they study most

HER2-Positive Primary Breast Cancer, Non-Small Cell Lung Cancer, Residual Invasive Breast Cancer

Studies at this site

• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling